These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 35956914)

  • 1. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
    Crocetti L; Floresta G; Cilibrizzi A; Giovannoni MP
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
    Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
    Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 4 inhibitors.
    Zebda R; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the development of phosphodiesterase-4 inhibitors.
    Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
    Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
    Page CP; Spina D
    Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection.
    Youn C; Dikeman DA; Chang E; Liu H; Nolan SJ; Alphonse MP; Joyce DP; Liu Q; Meixiong J; Dong X; Miller LS; Archer NK
    Exp Dermatol; 2023 Apr; 32(4):425-435. PubMed ID: 36461082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
    Kubota-Ishida N; Kaji C; Matsumoto S; Wakabayashi T; Matsuhira T; Okura I; Cho N; Isshiki S; Kumura K; Tabata Y
    Eur J Pharmacol; 2024 Jan; 962():176202. PubMed ID: 37996010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.
    Banner KH; Press NJ
    Br J Pharmacol; 2009 Jul; 157(6):892-906. PubMed ID: 19508401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
    Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
    Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
    Parikh N; Chakraborti AK
    Curr Med Chem; 2016; 23(2):129-41. PubMed ID: 26572614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases.
    Fan T; Wang W; Wang Y; Zeng M; Liu Y; Zhu S; Yang L
    Front Pharmacol; 2024; 15():1407871. PubMed ID: 38915460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
    Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
    JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Calzetta L; Rogliani P; Matera MG
    Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis.
    Hiyama H; Arichika N; Okada M; Koyama N; Tahara T; Haruta J
    J Pharmacol Exp Ther; 2023 Jul; 386(1):45-55. PubMed ID: 37041087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
    Abbott-Banner KH; Page CP
    Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.
    Li H; Zuo J; Tang W
    Front Pharmacol; 2018; 9():1048. PubMed ID: 30386231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 4 inhibitors in diabetic nephropathy.
    Ookawara M; Nio Y
    Cell Signal; 2022 Feb; 90():110185. PubMed ID: 34785349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.